Medmix Ag · SIX:MEDX
Medmix — UBS Swiss Equity Technology and Innovation Days 2023
16 slides from Medmix's conference presentation, Nov 14, 2023
Slide 1: medmix technology
medmix technology Dominik Vonier Head of Drug Delivery 14 November 2023 Providing innovative solutions to help people live healthier and more confident lives medmix CONFIDENTIAL
Slide 2: Disclaimer and other important notes
Disclaimer and other important notes This presentation contains forward-looking statements that are based on management’s current assumptions and expectations concerning future developments, including but not limited to, projections of financial developments, market activities or future performance
Slide 3: Our aspiration, mission and vision
medmix Our aspiration, mission and vision ASPIRATION Be the global leader in high precision delivery devices for the healthcare, consumer & industrial end markets MISSION Provide innovative solutions to help millions of people live a healthier and more confident life VISION Deliver innovative, relia
Slide 4: Our key figures
medmix Key figures Global Our key figures footprint 14 ~2,600 employees production, logistics & distribution sites 22% ~2.5bn CHF 477m revenues in 2022 adj. EBITDA margin in 2022 products per year ~900 active patents 4 medmix CONFIDENTIAL
Slide 5: medmix Business Structure: Our segments
medmix Business Structure Our segments HEALTHCARE CONSUMER AND INDUSTRIAL DRUG DELIVERY SURGERY DENTAL INDUSTRY BEAUTY Award-winning, Pioneer in bone cement Gold standard in Leading in industrial Leading microbrush proprietary injection mixing devices dental mixing mixing and dispensing specialist p
Slide 6: Drug Delivery - Overview
Drug Delivery - Overview Haselmeier, a medmix brand • Strong growth since acquisition in 2020 – re-positioning towards higher volumes • Expanding product portfolio and ramping-up production capabilities • Establish Haselmeier as preferred partner for our customers and their patients • New autoinject
Slide 7: Haselmeier Strategy: Complete and flexible offering
Haselmeier Strategy: Complete and flexible offering For our customers and their patients Become the preferred partner for pen and autoinjector solutions • Be the preferred partner for all complex solutions: nothing too complex or too small • Focus on impactful and high-value indications, eg obesity,
Slide 8: Haselmeier Portfolio: Products and services
Haselmeier Portfolio: Products and services We cover all needs for our customers and their patients Injection Pens Autoinjectors Digital Solutions Services Customization: Design & Development Regulatory Affairs & Quality Support Final Assembly & 8Packaging 8 medmix CONFIDENTIAL
Slide 9: Platforms tailored to customer and patients' needs
Platforms tailored to customer and patients’ needs Product Platforms Technology Platforms • Lower capital expenditure • Flexible customization options • Lower development costs • Flexible financial models • Faster time to market • More flexible in regional sourcing 9 medmix CONFIDENTIAL
Slide 10: Focus on PiccoJect autoinjector
Focus on PiccoJect™ autoinjector Why an autoinjector? • Simplifies at-home injection • Ready to use • Patient ease-of-use • Safe • Exact dosing • Ideal for GLP-1 and biologics 10 10 medmix CONFIDENTIAL
Slide 11: PiccoJect – Excellence through Simplicity
PiccoJect™ – Excellence through Simplicity Promotion Video To play the video please click on this link in our FIND OUT MORE section: Fireside-chat from the UBS Swiss Equity Technology and Innovation Days, Nov 14, 2023 – Video PiccoJect 11 medmix CONFIDENTIAL
Slide 12: PiccoJect – Excellence through Simplicity
PiccoJect™ – Excellence through Simplicity Important for customers Important for patients Next generation device with competitive USPs Only 8 parts Large wrap-around Ergonomic shape in total drug window and small size Committed to Two audible sustainability clicks Connectivity Colored status Optimiz
Slide 13: High patient preference for PiccoJect
High patient preference for PiccoJect™ Confirmed by human factor studies 92% 83% 75% 96% overall preference rated drug window preferred the wide expressed very high for PiccoJect™ visibility as cross-section willingness for superior daily use Patient It is really easy, testimonials since my stroke m
Slide 14: Focus on D-Flex
Focus on D-Flex™ Unique disposable pen allowing only intended doses One fixed or Visual feedback Only the intended several fixed-doses during injection and dose(s) can be set in just one pen at dose completion Fast adaptation: Assisted injection to Connectivity Only one part needs reduce necessary o
Slide 15: Q&A
Q&A Dominik Vonier Head of Drug Delivery 15 medmix CONFIDENTIAL
Slide 16: Your Investor Relations Contact
Your Investor Relations Contact James Amoroso Investor Relations, medmix Phone: +41 41 723 73 57 E-mail: investorrelations@medmix.com medmix Group AG Neuhofstrasse 20 6340 Baar Switzerland 16 medmix CONFIDENTIAL
medmix — UBS Swiss Equity Technology and Innovation Days 2023 on 6ix